Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurosci ; 35(26): 9580-94, 2015 Jul 01.
Article in English | MEDLINE | ID: mdl-26134641

ABSTRACT

Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nociceptive pathways. Here, we demonstrate dose-dependent, bimodal effects of buprenorphine on transmission at C-fiber synapses in rat spinal cord dorsal horn in vivo. At an analgesically active dose of 1500 µg·kg(-1), buprenorphine reduced the strength of spinal C-fiber synapses. This depression required activation of spinal opioid receptors, putatively µ1-opioid receptors, as indicated by its sensitivity to spinal naloxone and to the selective µ1-opioid receptor antagonist naloxonazine. In contrast, a 15,000-fold lower dose of buprenorphine (0.1 µg·kg(-1)), which caused thermal and mechanical hyperalgesia in behaving animals, induced an enhancement of transmission at spinal C-fiber synapses. The ultra-low-dose buprenorphine-induced synaptic facilitation was mediated by supraspinal naloxonazine-insensitive, but CTOP-sensitive µ-opioid receptors, descending serotonergic pathways, and activation of spinal glial cells. Selective inhibition of spinal 5-hydroxytryptamine-2 receptors (5-HT2Rs), putatively located on spinal astrocytes, abolished both the induction of synaptic facilitation and the hyperalgesia elicited by ultra-low-dose buprenorphine. Our study revealed that buprenorphine mediates its modulatory effects on transmission at spinal C-fiber synapses by dose dependently acting on distinct µ-opioid receptor subtypes located at different levels of the neuraxis.


Subject(s)
Analgesics, Opioid/pharmacology , Buprenorphine/pharmacology , Pain Threshold/drug effects , Synapses/drug effects , Animals , Animals, Newborn , Astrocytes/drug effects , Dose-Response Relationship, Drug , Hyperalgesia/drug therapy , In Vitro Techniques , Male , Naloxone/analogs & derivatives , Naloxone/pharmacology , Nerve Fibers, Unmyelinated/drug effects , Nerve Fibers, Unmyelinated/metabolism , Pain Measurement/drug effects , Phosphopyruvate Hydratase/metabolism , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effects , Spinal Cord/cytology , Spinal Nerve Roots/cytology , Time Factors
2.
J Neurosci ; 35(11): 4552-70, 2015 Mar 18.
Article in English | MEDLINE | ID: mdl-25788673

ABSTRACT

Synaptic plasticity is thought to be initiated by neurons only, with the prevailing view assigning glial cells mere specify supportive functions for synaptic transmission and plasticity. We now demonstrate that glial cells can control synaptic strength independent of neuronal activity. Here we show that selective activation of microglia in the rat is sufficient to rapidly facilitate synaptic strength between primary afferent C-fibers and lamina I neurons, the first synaptic relay in the nociceptive pathway. Specifically, the activation of the CX3CR1 receptor by fractalkine induces the release of interleukin-1ß from microglia, which modulates NMDA signaling in postsynaptic neurons, leading to the release of an eicosanoid messenger, which ultimately enhances presynaptic neurotransmitter release. In contrast to the conventional view, this form of plasticity does not require enhanced neuronal activity to trigger the events leading to synaptic facilitation. Augmentation of synaptic strength in nociceptive pathways represents a cellular model of pain amplification. The present data thus suggest that, under chronic pain states, CX3CR1-mediated activation of microglia drives the facilitation of excitatory synaptic transmission in the dorsal horn, which contributes to pain hypersensitivity in chronic pain states.


Subject(s)
Excitatory Postsynaptic Potentials/physiology , Microglia/physiology , Synaptic Transmission/physiology , Animals , Male , Neuronal Plasticity , Organ Culture Techniques , Rats , Rats, Sprague-Dawley , Spinal Cord/cytology , Spinal Cord/physiology
3.
Hum Mol Genet ; 21(22): 4939-47, 2012 Nov 15.
Article in English | MEDLINE | ID: mdl-22914735

ABSTRACT

Huntington's disease (HD) is a progressive neurodegenerative disorder caused by trinucleotide repeat (TNR) expansions. We show here that somatic TNR expansions are significantly reduced in several organs of R6/1 mice lacking exon 2 of Nei-like 1 (Neil1) (R6/1/Neil1(-/-)), when compared with R6/1/Neil1(+/+) mice. Somatic TNR expansion is measured by two different methods, namely mean repeat change and instability index. Reduced somatic expansions are more pronounced in male R6/1/Neil1(-/-) mice, although expansions are also significantly reduced in brain regions of female R6/1/Neil1(-/-) mice. In addition, we show that the lack of functional Neil1 significantly reduces germline expansion in R6/1 male mice. In vitro, purified human NEIL1 protein binds and excises 5-hydroxycytosine in duplex DNA more efficiently than in hairpin substrates. NEIL1 excision of cytosine-derived oxidative lesions could therefore be involved in initiating the process of TNR expansion, although other DNA modifications might also contribute. Altogether, these results imply that Neil1 contributes to germline and somatic HD CAG repeat expansion.


Subject(s)
DNA Glycosylases/genetics , Genomic Instability , Huntington Disease/genetics , Mutation , Trinucleotide Repeat Expansion/genetics , Animals , Base Sequence , DNA Glycosylases/metabolism , Disease Models, Animal , Female , Germ-Line Mutation , Huntington Disease/metabolism , Male , Mice , Mice, Knockout
SELECTION OF CITATIONS
SEARCH DETAIL
...